SCHEMBL2226562

SCHEMBL2226562

COc1ccc2[nH]cc(S(=O)(=O)c3ccc(OC)c(NC4CCNCC4)c3)c2c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
HTR4 Q13639 3/20 0.50
TP53 P04637 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
HTR6 P50406 3/20 0.44
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
GAA P10253 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
PTGER3 P43115 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NR4A2 P43354 1/20 0.37
MMP2 P08253 1/20 0.37
MMP13 P45452 1/20 0.37
MMP14 P50281 1/20 0.37
ADAM17 P78536 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223322 0.89 MAPT (0.53) MAPTTP53SMN1; SMN2LMNAHTT
SCHEMBL2225188 0.84 CYP3A4 (0.45) TP53LMNAHTR6
SCHEMBL2222544 0.82 CYP3A4 (0.46) MAPTTP53SMN1; SMN2LMNAHTT
SCHEMBL2226273 0.81 MAPT (0.48) MAPTTP53SMN1; SMN2LMNAHTT
SCHEMBL2223312 0.80 MAPT (0.56) MAPTHTR4TP53SMN1; SMN2LMNA
SCHEMBL2222361 0.80 MAPT (0.53) MAPTHTR4TP53SMN1; SMN2LMNA
SCHEMBL2223438 0.80 MAPT (0.53) MAPTTP53SMN1; SMN2LMNAHTT
SCHEMBL2222402 0.79 KCNH2 (0.60) MAPTSMN1; SMN2LMNAHTTHTR6
SCHEMBL28920424 0.79 MAPT (0.59) MAPTTP53SMN1; SMN2LMNAHTT
SCHEMBL30091329 0.79 MAPT (0.59) MAPTTP53SMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2521714-B1 Aromatic sulfone compounds useful in the treatment of central nervous disorders SUVEN LIFE SCIENCES LTD (IN) 2015-08-12 EP claimed
US-9018231-B2 Sulfone compounds as 5-HT6 receptor ligands SUVEN LIFE SCIENCES LIMITED (IN) 2015-04-28 US claimed
US-20130005709-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2013-01-03 US claimed
EP-2521714-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS Suven Life Sciences Limited (IN) 2012-11-14 EP claimed
WO-2011083487-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2011-07-14 WO claimed
EP-2521714-B1 Aromatic sulfone compounds useful in the treatment of central nervous disorders SUVEN LIFE SCIENCES LTD (IN) 2015-08-12 EP disclosed
US-9018231-B2 Sulfone compounds as 5-HT6 receptor ligands SUVEN LIFE SCIENCES LIMITED (IN) 2015-04-28 US disclosed
US-20130005709-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2013-01-03 US disclosed
EP-2521714-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS Suven Life Sciences Limited (IN) 2012-11-14 EP disclosed
WO-2011083487-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005709-A1 SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS HTR6, HTR5A, HTR1A MAPT 509/4885HTR4 5/4885TP53 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.